Hanneke Schuitemaker, Ph.D., Vice President, Global Head Viral Vaccine Discovery and Translational Medicine at Janssen Vaccines.
Hanneke Schuitemaker is the Global Head of Viral Vaccine Discovery and Translational Medicine in the Infectious Disease and Vaccines Therapeutic Area of Janssen Vaccines and also a member of the Global Public Health Senior Leadership team. In addition, she is a Professor in Virology at the Academic Medical Center of the University of Amsterdam (since 2004). She joined Crucell on September 1, 2010, which was acquired by Johnson and Johnson in February 2011.
Hanneke Schuitemaker is a medical biologist by training, received her PhD in Medicine in 1992 at the University of Amsterdam and worked for more than 20 years on HIV-1 pathogenesis, first at Sanquin (1989-2007), the blood supply foundation in the Netherlands, where since 1998 she was the chair of the department of Clinical Viro-Immunology, and then at the AMC (since 2007), where she was the chair of the Department of Experimental Immunology and a member of the Research Council.
From mid-2003 to mid-2004, she worked as a visiting scientist at The Scripps Research Institute in La Jolla, California. She successfully trained 25 PhD students, co-authored more than 275 peer reviewed scientific articles (can be found at http://www.ncbi.nlm.nih.gov/pubmed, under Schuitemaker h) and received multiple and prestigious grants.
She is a member of the scientific advisory board of the International AIDS Vaccine Initiative (IAVI).
In her current position, she is responsible for the port-folio of viral vaccine programs that are in the phase of discovery or early development. Most advanced programs in that port-folio are prophylactic and/or therapeutic vaccine candidates for Multivalent filo, Ebola, HIV, RSV, sIPV and HPV.